CLL Support Association

Dr. Matt Davids on the combination of TGR-102 and ibrutinib


This week, we are sharing a video interview with Dr. Matthew Davids from ASH 2016 where we discuss a clinical trial that combines two targeted therapies for treating relapsed/refractory CLL, ibrutinib and TGR-1202. You can read the summary and watch the video or read the transcript here:

TOMORROW, we'll be publishing the first 2017 issue of The CLL Tribune and marking the 2 year anniversary since our website went live! Watch for it!

WOW! Two years online.

Stay strong.

We are all in this together.


1 Reply

Very good video, Dr. Koffman. Thanks for sharing that with us. As a 3-yr. ibrutinib SLL patient, I am very interested in combination therapies, and hoping and praying that one day there will be a successful combination that puts CLL/SLL patients into lasting remissions.

Lynn B


You may also like...